RGEN · Repligen Q2 FY2026 earnings call record财报电话会记录

“Additional information concerning risks related to our business is included in our quarterly reports on Form 10-Q, our annual report on Form 10-K, and our current reports, including the Form 8-K that we are filing today, and other filings that we make with the Securities and Exchange Commission.”

“Our team executed at a high level, driving 12% reported growth, which translated to 13% organic growth and 460 basis points of adjusted operating margin expansion.”

“From our analysis of the biotech landscape, it's clear that cell therapy represents a meaningful portion of our customers' focus and investment, with this modality representing nearly a quarter of their clinical pipelines.”

“As I previously mentioned, we're encouraged by the recent pickup in orders that will start fueling the 2027 backlog for both of these product categories.”

“This is a reported year-over-year growth of 12% or 13% growth on an organic basis, which excludes the impact of acquisitions, divestitures, and foreign exchange.”

“The second quarter adjusted gross profit was $110 million, and the adjusted gross margin was 53.9%.”

“This translated to an adjusted operating margin of 16.7% in the second quarter, which was an increase of 460 basis points year-over-year on a reported basis, including a 40 basis point benefit from the sale of Polymem.”

“Underlying our adjusted operating income margin expansion in the quarter was strong operating leverage, achieved with a modest adjusted OpEx growth of 6% on a reported basis and 8% excluding the impact from the Polymem sale and foreign currency.”

“This represents 10%-13% reported growth, or 10.5%-13.5% organic, which is an increase of a full percentage point of organic growth at the midpoint versus our prior guidance.”

“That said, with our strong first-half results, we are raising our adjusted operating income guidance to a range of $128 million-$134 million and our adjusted operating margin guidance of 15.7%-16%.”

“As it relates to cash, we expect CapEx spend to continue being approximately 3%-4% of 2026 revenue.”

“Just to be very specific on ATF, in the first half of 2026, we’ve won more new programs/customers than we did in the first half of 2025.”